Article Text

Download PDFPDF
Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity
  1. J M Péron1,
  2. C Bureau1,
  3. P Gourdy3,
  4. H Lulka1,
  5. A Souque1,
  6. B Calippe3,
  7. J Selves5,
  8. T Al Saati5,
  9. J Bernad2,
  10. P Cordelier1,
  11. B Couderc4,
  12. L Pradayrol1,
  13. B Pipy2,
  14. L Buscail1,
  15. J P Vinel1
  1. 1INSERM U531, Toulouse, France
  2. 2UPRES-EA 2405, Toulouse, France
  3. 3INSERM U589, Toulouse, France
  4. 4INSERM U563, Toulouse, France
  5. 5INSERM U563, Toulouse, France
  1. Correspondence to:
    Dr J-M Péron
    Service d′Hépato-Gastro-Entérologie and INSERM U531, Hôpital Purpan, CHU Toulouse, Place du Dr Baylac, 31 100 Toulouse, France;{at}


Background: Peritoneal carcinomatosis from pancreatic cancer has a poor prognosis with a median survival of 3.1 months. This is mainly due to lack of effective treatment. Interleukin 12 (IL12) is a proinflammatory cytokine that has a potent antitumoral effect by stimulating innate and adoptive immunity.

Aim: To examine the antitumoral effect and toxicity of intraperitoneal delivery of IL12 using an ex vivo gene therapy approach in a murine model of pancreatic peritoneal carcinomatosis.

Methods: Peritoneal carcinomatosis was generated by direct intraperitoneal inoculation of the pancreatic cancer cell line Capan-1 in athymic mice. Syngenic fibroblasts were genetically modified in vitro to secrete IL12 using a polycistronic TFG murine IL12 retroviral vector coding for both p35 and p40 murine IL12 subunits. Ex vivo gene therapy involved injection of the genetically modified fibroblasts intraperitoneally twice a week for 4 weeks.

Results: Treatment of pre-established peritoneal carcinomatosis with fibroblasts genetically modified to express IL12 induced a marked inhibition of tumour growth as measured by comparison of the weights of the intraperitoneal tumour nodules in the treated and control animals (3.52 (SD 0.47) v 0.93 (SD 0.21) g, p<0.05) and improved survival. This effect was associated with infiltration of the peritoneal tumour nodules with macrophages. Peritoneal lavage confirmed enhancement of the innate peritoneal inflammatory activity, with an increased number of activated macrophages and natural killer cells. Moreover, macrophages harvested from animals with peritoneal carcinomatosis and treated with IL12-expressing fibroblasts expressed an activated proinflammatory antitumoral M1 phenotype that included strongly enhanced reactive oxygen species and nitric oxide production. There was no treatment-related toxicity.

Conclusion: Multiple injections of genetically modified fibroblasts to express IL12 is an effective and well-tolerated treatment for experimental murine pancreatic peritoneal carcinomatosis via activated innate immunity and in particular activated M1 macrophages.

  • FCS, fetal calf serum
  • HPF, high-power field
  • IFN, interferon
  • IL12, interleukin 12
  • IRES, internal ribosome entry site sequences
  • LPS, lipopolysaccharide
  • Neo, neomycin
  • PBS, phosphate-buffered saline
  • PMA, pharbol myristate acetate
  • ROS, reactive oxygen species
  • SFM, serum-free medium
  • TNF, tumour necrosis factor

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 4 August 2006

  • Funding: This work was supported in part by grants from LNCC, Région Midi-Pyrénées (programme concerté de thérapie génique et cellulaire), Cancéropole Grand sud Ouest and grants from the Ligue Régional de Lutte contre le Cancer and Région midi Pyrénée.

  • Competing interests: None declared.

Linked Articles

  • Digest
    Robin Spiller Alastair Watson